Aarti Drugs Approves FY26 Audited Results & Reappoints Cost & Internal Auditors
Aarti Drugs Limited's Board approved audited standalone and consolidated financial results for FY26. They re-appointed M/s GMVP & Associates LLP as Cost Auditor for FY27 and M/s Raman S. Shah & Co. as Internal Auditor for three years from April 1, 2026. The Risk Management Committee was also reconstituted.
The announcement pertains to routine financial reporting and auditor re-appointments, which are standard corporate governance procedures and do not involve significant strategic shifts or major financial events.
The announcement details the approval of financial results and routine auditor re-appointments, with no significant positive or negative financial performance indicators highlighted.
Aarti Drugs Limited announced the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, following a Board of Directors meeting held on May 15, 2026. The company approved its financial statements, including the statement of assets and liabilities and cash flow statements, along with the auditor's report, which declared an unmodified opinion.
Further, the Board approved the re-appointment of M/s GMVP & Associates LLP as the Cost Auditor for the financial year ending March 31, 2027. Additionally, M/s Raman S. Shah & Co. was re-appointed as the Internal Auditor for a period of three consecutive financial years starting April 1, 2026. The company also reconstituted its Risk Management Committee with the immediate inclusion of Shri Narendra J. Salvi as a member.
The Board meeting commenced at 2:50 PM and concluded at 4:40 PM on May 15, 2026. The financial results will be published in newspapers and uploaded on the company's website and the stock exchange websites.
What to do with a filing like this
Aarti Drugs Limited filed this with the NSE as a statutory disclosure, categorised under standalone results. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Drugs Limited. Read the original for the full detail.